• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neurology - Pipeline Review, H2 2012 Product Image

Neurology - Pipeline Review, H2 2012

  • Published: December 2012
  • 526 pages
  • Global Markets Direct

Neurology – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Neurology - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neurology, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurology. Neurology - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neurology.
- A review of the Neurology products under development by companies and universities/research institutes based on information derived from company and READ MORE >

2
List of Tables 14
List of Figures 22
Introduction 23
REPORT COVERAGE 23
Neurology Overview 24
Therapeutics Development 25
An Overview of Pipeline Products for Neurology 25
Neurology Therapeutics under Development by Companies 27
Neurology Therapeutics under Investigation by Universities/Institutes 49
Late Stage Products 57
Comparative Analysis 57
Mid Clinical Stage Products 58
Comparative Analysis 58
Early Clinical Stage Products 59
Comparative Analysis 59
Discovery and Pre-Clinical Stage Products 60
Comparative Analysis 60
Neurology Therapeutics – Products under Development by Companies 61
Neurology Therapeutics – Products under Investigation by Universities/Institutes 92
Companies Involved in Neurology Therapeutics Development 101
Bristol-Myers Squibb Company 101
Genzyme Corporation 102
Boehringer Ingelheim GmbH 103
F. Hoffmann-La Roche Ltd. 104
Kyowa Hakko Kirin Co., Ltd. 105
Abbott Laboratories 106
Biogen Idec Inc. 107
Allergan, Inc. 108
OXIS International, Inc. 109
NsGene A/S 110
Sanofi-Aventis 111
AstraZeneca PLC 112
GlaxoSmithKline plc 113
Genentech, Inc. 114
Quark Pharmaceuticals, Inc. 115
Apotex, Inc. 116
Merck & Co., Inc. 117
Dainippon Sumitomo Pharma Co., Ltd. 118
Taisho Pharmaceutical Co., Ltd. 119
Oxford BioMedica plc 120
Sangamo BioSciences, Inc. 121
ExonHit Therapeutics SA 122
Vectura Group plc 123
XenoPort, Inc. 124
BioLineRx, Ltd. 125
Avineuro Pharmaceuticals, Inc. 126
Reliance Life Sciences Pvt. Ltd. 127
Sylentis 128
Neurocrine Biosciences, Inc. 129
Novartis AG 130
Aphios Corporation 131
AcelRx Pharmaceuticals, Inc. 132
EnVivo Pharmaceuticals 133
Cubist Pharmaceuticals, Inc. 134
Depomed, Inc. 135
Eisai Co., Ltd. 136
Elan Corporation, plc 137
Galenica Ltd. 138
H Lundbeck A/S 139
Merz GmbH & Co. KGaA 140
Orion Corporation 141
Pfizer Inc. 142
Sigma-Tau S.p.A. 143
Teva Pharmaceutical Industries Limited 144
UCB Group 145
Vertex Pharmaceuticals Incorporated 146
Sun Pharmaceutical Industries Limited 147
Hadasit Medical Research Services & Development Ltd 148
IMPAX Laboratories, Inc. 149
CEL-SCI Corporation 150
Shire Plc 151
Vernalis plc 152
OPKO Health, Inc. 153
BrainStorm Cell Therapeutics Inc. 154
NuPathe Inc. 155
Aeolus Pharmaceuticals, Inc. 156
Merck KGaA 157
Addex Pharmaceuticals 158
Evotec Aktiengesellschaft 159
GW Pharmaceuticals plc 160
Hemispherx Biopharma, Inc. 161
Hollis-Eden Pharmaceuticals, Inc. 162
Anavex Life Sciences Corp. 163
Advinus Therapeutics Pvt. Ltd. 233
Avanti Therapeutics 234
SCYNEXIS, Inc. 235
Chipscreen Biosciences Ltd 236
Arbor Pharmaceuticals, Inc. 237
KeyNeurotek Pharmaceuticals AG 238
Upsher-Smith Laboratories, Inc. 239
Palau Pharma S.A 240
Seaside Therapeutics 241
Osmotica Pharmaceutical Corp. 242
Snowdon Inc. 243
Domain Therapeutics 244
Pharmagenesis, Inc. 245
Physica Pharma 246
BioMAS Ltd. 247
Wellstat Therapeutics Corporation 248
Celon Pharma Sp. z o.o. 249
Xenon Pharmaceuticals Inc. 250
Oncodesign SA 251
BIOALVO S.A. 252
Trophos SA 253
Theraptosis S.A. 282
Adamas Pharmaceuticals, Inc. 283
QR Pharma, Inc. 284
NeuroNascent, Inc. 285
Siena Biotech S.p.A. 286
Concert Pharmaceuticals, Inc. 287
NovaLead Pharma Pvt. Ltd. 288
KineMed, Inc. 289
Dart NeuroScience LLC 290
QRxPharma Limited 291
Omeros Corporation 292
Xencor, Inc. 293
Acetylon Pharmaceuticals, Inc. 294
Adeona Pharmaceuticals, Inc. 295
Intra-Cellular Therapies, Inc. 296
Targacept, Inc. 297
N-Gene Research Laboratories, Inc. 298
Obio Pharmaceutical Holdings Limited. 299
Cellceutix Corporation 300
Biovista Inc. 301
SanBio, Inc. 302
Asklepios BioPharmaceutical, Inc. 303
KYORIN Pharmaceutical Co., Ltd. 304
Tautatis Incorporated 305
Marinus Pharmaceuticals, Inc. 306
Maruishi Pharmaceutical Co., Ltd. 307
Nexgenix Pharmaceuticals, LLC 308
Proteostasis Therapeutics, Inc. 309
M's Science Corporation 310
NasVax Ltd. 311
Stelic Institute & Co. 312
NeuroHealing Pharmaceuticals Inc. 313
NeuroTherapeutics Pharma Inc. 314
Cannasat Therapeutics, Inc. 315
Kuhnil Pharmaceutical Co., Ltd. 316
Cenomed, Inc. 317
Bial - Portela & Ca, S.A. 318
Pharnext SAS 319
Sihuan Pharmaceutical Holdings Group Ltd. 320
Heptares Therapeutics Ltd. 321
Ascendis Pharma A/S 322
Signum Biosciences, Inc. 323
Envoy Therapeutics, Inc. 324
Neuraltus Pharmaceuticals, Inc. 325
RhinoCyte, Inc. 326
ArmaGen Technologies, Inc. 327
Prosetta Corporation 328
Clera Inc. 329
Ausio Pharmaceuticals, LLC 330
Celtic Pharmaceutical Holdings L.P. 331
Beech Tree Labs, Inc. 332
Errant Gene Therapeutics, LLC 333
Biolab Farmaceutica 334
Vichem Chemie Research Ltd. 335
BIOPROJET SCR 336
Varinel, Inc. 337
Mt Cook Pharma. Inc. 338
FunZyme BioTechnologies S.A. 339
Immune Technologies and Medicine 340
Psyadon Pharmaceuticals, Inc. 341
Sigmoid Pharma. 342
Naurex, Inc. 343
Socratech, L.L.C. 344
STATegics, Inc. 345
PharmaNeuroBoost N.V. 346
UNeMed 347
Neurology – Therapeutics Assessment 348
Assessment by Monotherapy Products 348
Assessment by Combination Products 349
Assessment by Route of Administration 350
Assessment by Molecule Type 352
Drug Profiles 354
(carbidopa + levodopa) - Drug Profile 354
Product Description 354
Mechanism of Action 354
R&D Progress 354
(carbidopa + levodopa) - Drug Profile 356
Product Description 356
Mechanism of Action 356
R&D Progress 356
lacosamide - Drug Profile 358
Product Description 358
Mechanism of Action 358
R&D Progress 358
brivaracetam - Drug Profile 361
Product Description 361
Mechanism of Action 361
R&D Progress 361
alemtuzumab - Drug Profile 431
Product Description 431
Mechanism of Action 431
R&D Progress 431
eslicarbazepine acetate - Drug Profile 432
Product Description 432
Mechanism of Action 432
R&D Progress 432
eslicarbazepine acetate - Drug Profile 434
Product Description 434
Mechanism of Action 434
R&D Progress 434
amantadine hydrochloride - Drug Profile 436
Product Description 436
Mechanism of Action 436
R&D Progress 436
AR-02 - Drug Profile 437
Product Description 437
Mechanism of Action 437
R&D Progress 437
carbamazepine - Drug Profile 444
Product Description 444
Mechanism of Action 444
R&D Progress 444
Neurology Therapeutics – Drug Profile Updates 446
Neurology Therapeutics – Discontinued Products 484
Neurology Therapeutics - Dormant Products 491
Neurology – Product Development Milestones 520
Featured News & Press Releases 520
Nov 20, 2012: NeuroDerm Announces Enrollment In Phase I Study Of ND0612 For Treatment Of Parkinson's Disease 520
Nov 20, 2012: Amarantus BioSciences Wins MANF Patent Challenge In Europe 520
Nov 16, 2012: LCT Receives Ethical Approval From New Zealand For NTCELL Phase I Trial In Parkinson’s Disease 521
Nov 14, 2012: Hermo Pharma Completes Recruitment For HER-801 Phase IIa Clinical Study 521
Nov 07, 2012: Depomed Reports Top Line Results From Phase II Study Of DM-1992 In Parkinson's Disease 521
Nov 05, 2012: Paion's Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan 522
Nov 05, 2012: Paion's Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan 522
Nov 05, 2012: Supernus Pharma Receives Two US Patents Covering Trokendi XR 522
Nov 01, 2012: Amarantus BioSciences Explores Orphan Drug Strategy Based On MANF Protein Folding 523
Nov 01, 2012: Omeros Announces Enrollment In Phase I Clinical Trial Evaluating OMS824 523
Appendix 525
Methodology 525
Coverage 525
Secondary Research 525
Primary Research 525
Expert Panel Validation 525
Contact Us 526
Disclaimer 526

List of Tables
Number of Products Under Development for Neurology, H2 2012 25
Products under Development for Neurology – Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Development by Companies, H2 2012 (Contd..4) 32
Number of Products under Development by Companies, H2 2012 (Contd..5) 33
Number of Products under Development by Companies, H2 2012 (Contd..6) 34
Number of Products under Development by Companies, H2 2012 (Contd..7) 35
Number of Products under Development by Companies, H2 2012 (Contd..8) 36
Number of Products under Development by Companies, H2 2012 (Contd..9) 37
Number of Products under Development by Companies, H2 2012 (Contd..10) 38
Number of Products under Development by Companies, H2 2012 (Contd..11) 39
Number of Products under Development by Companies, H2 2012 (Contd..12) 40
Number of Products under Development by Companies, H2 2012 (Contd..13) 41
Number of Products under Development by Companies, H2 2012 (Contd..14) 42
Number of Products under Development by Companies, H2 2012 (Contd..15) 43
Number of Products under Development by Companies, H2 2012 (Contd..16) 44
Number of Products under Development by Companies, H2 2012 (Contd..17) 45
Number of Products under Development by Companies, H2 2012 (Contd..18) 46
Number of Products under Development by Companies, H2 2012 (Contd..19) 47
Number of Products under Development by Companies, H2 2012 (Contd..20) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 56
Comparative Analysis by Late Stage Development, H2 2012 57
Comparative Analysis by Mid Clinical Stage Development, H2 2012 58
Comparative Analysis by Early Clinical Stage Development, H2 2012 59
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 60
Products under Development by Companies, H2 2012 61
Products under Development by Companies, H2 2012 (Contd..1) 62
Products under Development by Companies, H2 2012 (Contd..2) 63
Products under Development by Companies, H2 2012 (Contd..3) 64
Products under Development by Companies, H2 2012 (Contd..4) 65
Products under Development by Companies, H2 2012 (Contd..5) 66
Products under Development by Companies, H2 2012 (Contd..6) 67
Products under Development by Companies, H2 2012 (Contd..7) 68
Products under Development by Companies, H2 2012 (Contd..8) 69
Products under Development by Companies, H2 2012 (Contd..9) 70
Products under Development by Companies, H2 2012 (Contd..10) 71
Products under Development by Companies, H2 2012 (Contd..11) 72
Products under Development by Companies, H2 2012 (Contd..12) 73
Products under Development by Companies, H2 2012 (Contd..13) 74
Products under Development by Companies, H2 2012 (Contd..14) 75
Products under Development by Companies, H2 2012 (Contd..15) 76
Products under Development by Companies, H2 2012 (Contd..16) 77
Products under Development by Companies, H2 2012 (Contd..17) 78
Products under Development by Companies, H2 2012 (Contd..18) 79
Products under Development by Companies, H2 2012 (Contd..19) 80
Products under Development by Companies, H2 2012 (Contd..20) 81
Products under Development by Companies, H2 2012 (Contd..21) 82
Products under Development by Companies, H2 2012 (Contd..22) 83
Products under Development by Companies, H2 2012 (Contd..23) 84
Products under Development by Companies, H2 2012 (Contd..24) 85
Products under Development by Companies, H2 2012 (Contd..25) 86
Products under Development by Companies, H2 2012 (Contd..26) 87
Products under Development by Companies, H2 2012 (Contd..27) 88
Products under Development by Companies, H2 2012 (Contd..28) 89
Products under Development by Companies, H2 2012 (Contd..29) 90
Products under Development by Companies, H2 2012 (Contd..30) 91
Products under Investigation by Universities/Institutes, H2 2012 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 94
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 95
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 96
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 97
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 98
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 99
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 100
Bristol-Myers Squibb Company, H2 2012 101
Genzyme Corporation, H2 2012 102
Boehringer Ingelheim GmbH, H2 2012 103
F. Hoffmann-La Roche Ltd., H2 2012 104
Kyowa Hakko Kirin Co., Ltd., H2 2012 105
Abbott Laboratories, H2 2012 106
Biogen Idec Inc., H2 2012 107
Allergan, Inc., H2 2012 108
OXIS International, Inc., H2 2012 109
NsGene A/S, H2 2012 110
Sanofi-Aventis, H2 2012 111
AstraZeneca PLC, H2 2012 112
GlaxoSmithKline plc, H2 2012 113
Genentech, Inc., H2 2012 114
Quark Pharmaceuticals, Inc., H2 2012 115
Apotex, Inc., H2 2012 116
Merck & Co., Inc., H2 2012 117
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 118
Taisho Pharmaceutical Co., Ltd., H2 2012 119
Oxford BioMedica plc, H2 2012 120
Sangamo BioSciences, Inc., H2 2012 121
ExonHit Therapeutics SA, H2 2012 122
Vectura Group plc, H2 2012 123
XenoPort, Inc., H2 2012 124
BioLineRx, Ltd., H2 2012 125
Avineuro Pharmaceuticals, Inc., H2 2012 126
Reliance Life Sciences Pvt. Ltd., H2 2012 127
Sylentis, H2 2012 128
Neurocrine Biosciences, Inc., H2 2012 129
Novartis AG, H2 2012 130
Aphios Corporation, H2 2012 131
AcelRx Pharmaceuticals, Inc., H2 2012 132
EnVivo Pharmaceuticals, H2 2012 133
Cubist Pharmaceuticals, Inc., H2 2012 134
Depomed, Inc., H2 2012 135
Eisai Co., Ltd., H2 2012 136
Elan Corporation, plc, H2 2012 137
Galenica Ltd., H2 2012 138
H Lundbeck A/S, H2 2012 139
Merz GmbH & Co. KGaA, H2 2012 140
Orion Corporation, H2 2012 141
Pfizer Inc., H2 2012 142
Sigma-Tau S.p.A., H2 2012 143
Teva Pharmaceutical Industries Limited, H2 2012 144
UCB Group, H2 2012 145
Vertex Pharmaceuticals Incorporated, H2 2012 146
Sun Pharmaceutical Industries Limited, H2 2012 147
Hadasit Medical Research Services & Development Ltd, H2 2012 148
IMPAX Laboratories, Inc., H2 2012 149
CEL-SCI Corporation, H2 2012 150
Shire Plc, H2 2012 151
Vernalis plc, H2 2012 152
OPKO Health, Inc., H2 2012 153
BrainStorm Cell Therapeutics Inc., H2 2012 154
NuPathe Inc., H2 2012 155
Aeolus Pharmaceuticals, Inc., H2 2012 156
Merck KGaA, H2 2012 157
Addex Pharmaceuticals, H2 2012 158
Evotec Aktiengesellschaft, H2 2012 159
GW Pharmaceuticals plc, H2 2012 160
Hemispherx Biopharma, Inc., H2 2012 161
Hollis-Eden Pharmaceuticals, Inc., H2 2012 162
Anavex Life Sciences Corp., H2 2012 163
Proneuron Biotechnologies, Inc., H2 2012 164
Amicus Therapeutics, Inc., H2 2012 165
American Biogenetic Sciences, Inc., H2 2012 166
Genfit, H2 2012 167
International Stem Cell Corporation, H2 2012 168
AVANIR Pharmaceuticals, H2 2012 169
Ligand Pharmaceuticals Incorporated, H2 2012 170
Manhattan Pharmaceuticals, Inc., H2 2012 171
Living Cell Technologies Limited, H2 2012 172
Lixte Biotechnology Holdings, Inc., H2 2012 173
Bionomics Limited, H2 2012 174
MultiCell Technologies, Inc., H2 2012 175
Neuren Pharmaceuticals Limited, H2 2012 176
Neuro-Hitech, Inc., H2 2012 177
NeuroSearch A/S, H2 2012 178
NovaDel Pharma, Inc., H2 2012 179
Nymox Pharmaceutical Corporation, H2 2012 180
Ore Pharmaceuticals Inc, H2 2012 181
PAION AG, H2 2012 182
Paladin Labs Inc., H2 2012 183
Cortex Pharmaceuticals, Inc., H2 2012 184
ACADIA Pharmaceuticals Inc., H2 2012 185
MAP Pharmaceuticals, Inc., H2 2012 186
Alnylam Pharmaceuticals, Inc, H2 2012 187
CombinatoRx, Incorporated, H2 2012 188
ProteoTech, Inc., H2 2012 189
Yungjin Pharm Ind. Co., Ltd., H2 2012 190
KOLON LIFE SCIENCE INC., H2 2012 191
WhanIn Pharmaceutical Co., Ltd., H2 2012 192
NeoStem, Inc., H2 2012 193
Titan Pharmaceuticals, Inc., H2 2012 194
Phytopharm Plc, H2 2012 195
SYGNIS Pharma AG, H2 2012 196
Prana Biotechnology Limited, H2 2012 197
Green Cross Corporation, H2 2012 198
AnGes MG, Inc., H2 2012 199
Biotie Therapies Corp., H2 2012 200
Futura Medical plc., H2 2012 201
Transition Therapeutics Inc., H2 2012 202
Allon Therapeutics Inc., H2 2012 203
Neurim Pharmaceuticals (1991) Ltd., H2 2012 204
Suven Life Sciences Ltd., H2 2012 205
MediPost Co., Ltd., H2 2012 206
Proximagen Neuroscience plc., H2 2012 207
Santhera Pharmaceuticals Holding AG, H2 2012 208
Newron Pharmaceuticals S.p.A., H2 2012 209
Simcere Pharmaceutical Group, H2 2012 210
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 211
e-Therapeutics plc, H2 2012 212
NatureWise Biotech & Medicals Corp, H2 2012 213
Rexahn Pharmaceuticals, Inc., H2 2012 214
NeuroVive Pharmaceutical AB, H2 2012 215
Mithridion, Inc., H2 2012 216
Labtec GmbH, H2 2012 217
Lundbeck Inc., H2 2012 218
Paloma Pharmaceuticals, Inc., H2 2012 219
Oryzon, H2 2012 220
axxonis Pharma AG, H2 2012 221
M et P Pharma AG, H2 2012 222
TauRx Therapeutics Ltd, H2 2012 223
Ceregene, Inc., H2 2012 224
Asubio Pharmaceuticals, Inc., H2 2012 225
Angelini Group, H2 2012 226
AFFiRiS AG, H2 2012 227
Accera, Inc., H2 2012 228
Sonexa Therapeutics, Inc., H2 2012 229
Bio-Link, H2 2012 230
D-Pharm Ltd., H2 2012 231
StemCells, Inc., H2 2012 232
Advinus Therapeutics Pvt. Ltd., H2 2012 233
Avanti Therapeutics, H2 2012 234
SCYNEXIS, Inc., H2 2012 235

List of Figures
Number of Products under Development for Neurology, H2 2012 25
Products under Development for Neurology – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 49
Late Stage Products, H2 2012 57
Mid Clinical Stage Products, H2 2012 58
Early Clinical Stage Products, H2 2012 59
Discovery and Pre-Clinical Stage Products, H2 2012 60
Assessment by Monotherapy Products, H2 2012 348
Assessment by Combination Products, H2 2012 349
Assessment by Route of Administration, H2 2012 350
Assessment by Stage and Route of Administration, H2 2012 351
Assessment by Molecule Type, H2 2012 352
Assessment by Stage and Molecule Type, H2 2012 353

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos